Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Belharra Therapeutics
3985 Sorrento Valley Boulevard, Suite C
San Diego, CA 92121
Phone: 858-800-4340

Belharra Therapeutics, Inc. is a privately held drug discovery company pioneering a novel photoaffinity-based chemoproteomics platform to disrupt the drug discovery paradigm. Guided by a diverse team of biotech trailblazers, Belharra's proprietary discovery engine is uniquely capable of identifying novel, non-covalent small molecule starting points for developing transformative medicines to address previously difficult-to-treat diseases and conditions. The company's next generation chemoproteomics platform enables Belharra scientists to identify small molecule drug candidates for any binding site, on any protein, in any conformational state, in any cell type. Originating with Christopher G. Parker, Ph.D. and John Teijaro, Ph.D. at Scripps Research and pioneers in the field of chemical biology and serial biotech founders Benjamin Cravatt, Ph.D. at Scripps Research and Stuart Schreiber, Ph.D. at the Broad Institute of MIT and Harvard, the four co-founded Belharra Therapeutics in 2021 with a $50M Series A financing from Versant Ventures and incubation at Inception Therapeutics. Belharra is headquartered in the San Francisco Bay Area with its primary lab and offices in San Diego, California

Key Contact
Jeff Jonker
Funding Events

01/04/23 $50,000,000 Series A Genentech
Versant Ventures
01/04/23 $50,000,000 Series A Genentech
Versant Ventures